Immunai

ImmunaiImmunai
Immunai

Immunai

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Website
2019Active179New York, United States
Rate
Advertise here

About

Immunai decodes the human immune system at unprecedented scale and resolution to facilitate the development of next-generation immune-related therapeutics. Their platform supports drug discovery and development by identifying novel targets, evaluating preclinical candidates, and optimizing clinical trials. They partner with biopharmaceutical companies and research institutions to provide actionable recommendations for advancing therapies.

Technology stack

detected 2026-07-09
Email
Stack
Analytics
SEO
Cookie consent
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Immunai do?

Immunai decodes the human immune system at unprecedented scale and resolution to facilitate the development of next-generation immune-related therapeutics. Their platform supports drug discovery and development by identifying novel targets, evaluating preclinical candidates, and optimizing clinical trials. They partner with biopharmaceutical companies and research institutions to provide actionable recommendations for advancing therapies.

How much funding has Immunai raised?

Immunai has raised a total of $295M in funding. The most recent round on record is Series B.

Where is Immunai headquartered?

Immunai is headquartered in New York, United States.

When was Immunai founded?

Immunai was founded in 2019.

What industry does Immunai operate in?

Immunai operates in Healthcare, Immunology, Data, Analytics, Personalized Treatment, Drug Development.

How many employees does Immunai have?

Immunai has approximately 179 people on record.

What is Immunai's revenue?

StartupHub estimates Immunai's annual revenue at $65.1M (range $32.9M to $108.3M, 63% confidence), based on comparable companies in the sector.

What is Immunai's valuation?

StartupHub estimates Immunai's effective valuation at $601.5M (range $421.1M to $782.0M, 26% confidence), based on comparable companies in the sector.